Vis børsmeldingen
on management of the disease, improved risk stratification and therefore the
ability of the BLC procedure to help urologists and patients make well-informed
decisions. The American Urological Association Annual Congress 2025 was held
April 26-28, at the Venetian Convention & Expo Center in Las Vegas, NV, USA.
Three abstracts were presented from Photocure’s U.S. Blue Light Cystoscopy with
Cysview Registry, a large multicenter bladder cancer patient registry of real
-world data, established by Photocure in 2014 and projected to enroll 4,400
patients. In addition, the study protocol of a randomized controlled non
-inferiority trial comparing a multidisciplinary approach including PDD-guided
primary TURBT to reduce the patients’ burden of second resection including a
total of 327 patients has been presented. This investigator-initiated trial is
supported by Photocure.
The abstract sessions on Saturday, April 26:
“Upstaging and Risk Migration with BLC for NMIBC: Results from a prospective
multicenter registry” by Alireza Ghoreifi, Duke University
The study looked at 2,854 NMIBC* patients from the US Blue Light Cystoscopy with
Cysview Registry. A total of 201 (7%) patients had at least one malignant lesion
detected exclusively by BLC while having a negative WLC. These lesions (335 in
total) included carcinoma in-situ (CIS) (145; 43%), low-grade Ta (53; 16%), high
-grade Ta (95; 28%), high-grade T1 (37; 11%), and high-grade T2 (5; 1%). As a
result of BLC-enhanced detection, the rate of upgrading or upstaging to a more
advanced tumor using BLC was 9.3%. The authors concluded that resulting changes
in grade/stage could impact patient management, such as the appropriate
administration of intravesical therapy, duration of therapy, and when to perform
radical cystectomy. The results are expected to form the basis for further
studies on how Blue Light Cystoscopy can support precision diagnostics and
improve patient management in NMIBC.
Read the abstract:
https://www.auajournals.org/doi/abs/10.1097/01.JU.0001109740.05294.af.32
“Predicting Recurrence and Progression in Contemporary Patients with NMIBC
Undergoing Blue Light Cystoscopy-Aided Transurethral Resection of Bladder Tumor”
by Boris Gershman, Harvard University, Beth Israel Deaconess Medical Center
Although blue light cystoscopy (BLC) is recommended by clinical practice
guidelines to reduce recurrence, predictive models for patients undergoing BLC
are lacking. The authors developed predictive models for recurrence and
progression in patients treated with BLC using 1109 patients. Median age at
diagnosis was 71 years, and 198 (18%) patients were female. Tumor stage was Ta
in 658 (60%), T1 in 241 (22%), and pure CIS in 210 (19%) patients. 759 (71%)
patients had high-grade tumors, and 324 (29%) patients had multifocal disease.
Median follow-up for relapse-free survival (RFS) and progression-free survival
(PFS) was 18, and 24 months, respectively, during which time 360 recurrence and
79 progression events occurred. Results showed a greater number of tumors (unit
HR 1.09), and recurrent tumor status (HR 1.32) were associated with increased
risk of recurrence, while pure CIS (HR 0.69) and receipt of perioperative
intravesical chemotherapy (HR 0.76) were associated with decreased risk of
recurrence. In contrast, higher tumor stage (HR 3.88 for T1; HR 3.69 for T1+CIS)
and lymphovascular invasion (HR 3.88) were associated with increased risks of
progression. The impact of the data is that these models reflect contemporary
treatment standards and can inform personalized, risk-adapted management of
NMIBC.
Read the abstract:
https://www.auajournals.org/doi/abs/10.1097/01.JU.0001109740.05294.af.10
“Performance of the EORTC and CUETO Risk Prediction Models in Contemporary
Patients Undergoing Transurethral Resection of Bladder Tumor with Blue Light
Cystoscopy” by Boris Gershman, Harvard University, Beth Israel Deaconess Medical
Center
In a companion study, the performance of the BLC recurrence/ progression model
was compared against EORTC and CUETO, a pair of widely recognized risk tools for
predicting recurrence and progression in non-muscle invasive bladder cancer
(NMIBC). Out of total of 899 patients included from the BLC Registry, Ta was
found in 658 (73%) patients and T1 in 241 (27%) patients, and concomitant CIS
was present in 116 (13%) patients. Median follow-up for RFS and PFS was 18 and
24 months, respectively. The discrimination of the EORTC model was c=0.59 for
RFS and c=0.67 for PFS, while for the CUETO model it was c=0.53 for RFS and
c=0.72 for PFS. Thus, overall, in a contemporary cohort of patients undergoing
BLC-TURBT, the EORTC and CUETO models demonstrated poor performance in
predicting RFS and PFS.
Dr. Boris Gershman, principal author of these two abstracts commented: “Accurate
prediction of recurrence and progression risk is essential for the management of
non-muscle invasive bladder cancer. However, the established EORTC and CUETO
risk models demonstrated poor performance forecasting these outcomes among
contemporary patients receiving a TURBT with blue light cystoscopy. We therefore
used the multi-institutional Blue Light Cystoscopy Registry to develop modern
predictive models for recurrence and progression in patients treated with BLC.
Such tools as these reflect contemporary treatment paradigms, and can inform the
personalized, risk-adapted management of NMIBC.”
“At AUA and EAU 2025 congresses we have seen important expert alignment these
past weeks on the importance of early and accurate precision diagnosis in
bladder cancer, and the role of blue light cystoscopy. Accurate diagnosis and
risk stratification based on staging, grading impacts treatment decisions. It
matters increasingly, the more advanced individualized treatment options a
urologist is able to offer for the management of their patients’ bladder
cancer”, said Anders Neijber, Photocure’s Chief Medical Officer.
Read the abstract:
https://www.auajournals.org/doi/abs/10.1097/01.JU.0001109740.05294.af.18
On Monday, April 28, in “Clinical Trials in Progess”:
“VI-RADS followed by Photodynamic Transurethral Resection of Non-muscle Invasive
Bladder Cancer versus White-light Conventional and Second Resection: The CUT
-LESS Randomized Trial” by Francesco del Guidici et al. from “Sapienza”
University of Rome, Italy
The CUT-less trial aims to evaluate if second resection can be safely omitted in
selected patients by combining cross-sectional imaging and PDD-guided primary
TURB in order to reduce the burden of early repeated TURB for the patient.
This randomized controlled non-inferiority trial compares the short-term
recurrence rates when combining preoperative staging using multiparametic
magnetic resonance imaging (mpMRI) Vesical Imaging-Reporting and Data System (VI
-RADS) and PDD-guided primary TURB vs. mpMRI Vi-RADs and white-light TURB only
followed by second resection in patients which are candidates for second
resection in NMIBC. This study will include a total of 327 patients. Secondary
endpoints include comparative evaluation of mid- and long-term recurrence and
progression rates, health-related quality of life, and health-economic cost
-benefit analysis.
Read the abstract:
https://www.auajournals.org/doi/10.1097/01.JU.0001110440.53375.7d
Beyond this groundbreaking volume and value of new data related to BLC,
Photocure provided congress attendees with hands-on experience in the blue light
cystoscopy with Cysview procedure on its booth, that featured a Fortec Mobile
Equipment Demo of the Saphira HD equipment and rental option. In addition, other
tech talks and expert sessions by equipment partners featured more aspects of
blue light cystoscopy.
*NMIBC: Non-muscle invasive bladder cancer
**TURBT: trans-urethral resection of bladder tumors
Note to editors:
All trademarks mentioned in this release are protected by law and are registered
trademarks of Photocure ASA.
This press release may contain product details and information which are not
valid, or a product is not accessible, in your country. Please be aware that
Photocure does not take any responsibility for accessing such information which
may not comply with any legal process, regulation, registration or usage in the
country of your origin.
About Bladder Cancer
Bladder cancer ranks as the 8[th] most common cancer worldwide - the 5[th] most
common in men - with 1 949 000 prevalent cases (5-year prevalence rate)[1a],
614 000 new cases and more than 220 000 deaths in 2022.[1b]
Approx. 75% of all bladder cancer cases occur in men.[1] It has a high
recurrence rate with up to 61% in year one and up to 78% over five years.[2]
Bladder cancer has the highest lifetime treatment costs per patient of all
cancers.[3]
Bladder cancer is a costly, potentially progressive disease for which patients
have to undergo multiple cystoscopies due to the high risk of recurrence. There
is an urgent need to improve both the diagnosis and the management of bladder
cancer for the benefit of patients and healthcare systems alike.
Bladder cancer is classified into two types, non-muscle invasive bladder cancer
(NMIBC) and muscle-invasive bladder cancer (MIBC), depending on the depth of
invasion in the bladder wall. NMIBC remains in the inner layer of cells lining
the bladder. These cancers are the most common (75%) of all BC cases and include
the subtypes Ta, carcinoma in situ (CIS) and T1 lesions. In MIBC the cancer has
grown into deeper layers of the bladder wall. These cancers, including subtypes
T2, T3 and T4, are more likely to spread and are harder to treat.[4]
[1 ]Globocan. a) 5-year prevalence / b) incidence/mortality by population.
Available at: https://gco.iarc.fr/today, accessed [February 2024].
[2 ]Babjuk M, et al. Eur Urol. 2019; 76(5): 639-657
[3 ]Sievert KD et al. World J Urol 2009;27:295-300
[4 ]Bladder Cancer. American Cancer Society.
https://www.cancer.org/cancer/bladder-cancer.html
About Hexvix[®]/Cysview[®] (hexaminolevulinate HCl)
Hexvix/Cysview is a drug that preferentially accumulates in cancer cells in the
bladder, making them glow bright pink during Blue Light Cystoscopy (BLC[®]). BLC
with Hexvix/Cysview, compared to standard white light cystoscopy alone, improves
the detection of tumors and leads to more complete resection, fewer residual
tumors, and better management decisions.
Cysview is the tradename in the U.S. and Canada, Hexvix is the tradename in all
other markets. Photocure is commercializing Cysview/Hexvix directly in the U.S.
and Europe and has strategic partnerships for the commercialization of
Hexvix/Cysview in China, Chile, Australia, New Zealand and Israel. Please refer
to Our partners for further information on our
commercial partners.
About Photocure ASA
Photocure: The Bladder Cancer Company delivers transformative solutions to
improve the lives of bladder cancer patients. Our unique technology, making
cancer cells glow bright pink, has led to better health outcomes for patients
worldwide. Photocure is headquartered in Oslo, Norway and listed on the Oslo
Stock Exchange (OSE: PHO). For more information, please visit us at
www.photocure.com/news
For further information, please contact:
Dan Schneider
President and CEO
Photocure ASA
Email: ds@photocure.com
Erik Dahl
CFO
Photocure ASA
Tel: +4745055000
Email: ed@photocure.com
Media and IR enquiries:
Geir Bjørlo
Corporate Communications (Norway)
Tel: +47 91540000
Email: geir.bjorlo@corpcom.no
Kilde
